0000771856false00007718562024-12-112024-12-11


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): December 11, 2024
 
CHAMPIONS ONCOLOGY, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware 001-11504 52-1401755
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)
 
1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices)
 
Registrant’s telephone number, including area code: (201) 808-8400
 
N/A
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
    

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



INFORMATION TO BE INCLUDED IN THE REPORT
 
Item 2.02.Results of Operations and Financial Condition.
 
On December 11, 2024, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
 
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.
 
(d)Exhibits
The following exhibit is filed herewith:
 
Exhibit No.
 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  CHAMPIONS ONCOLOGY, INC.
  (Registrant)
   
Date: December 11, 2024
By:/s/ Ronnie Morris 
  Ronnie Morris 
  Chief Executive Officer 
 

Exhibit 99.1
    logobranding_headerleftali.jpg                 NEWS
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104


Champions Oncology Reports Quarterly Revenue of $13.5 Million
Adjusted EBITDA of $1.1 million


Hackensack, NJ – December 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.

Second Quarter and Recent Highlights:

•Total revenue increased 17% to $13.5 million
•Gross profit of $6.1 million; margin of 45%
•Net income of approximately $730,000
•Adjusted EBITDA of $1.1 million
•Development of new data revenue stream

First Half 2025 Highlights:

•Total revenue increased 14% to $27.6 million
•Gross profit of $13.1 million; margin of 47%
•Net income of $2.1 million
•Adjusted EBITDA of $3.2 million

Ronnie Morris, CEO of Champions, commented, “Our second quarter's performance solidified our confidence in the Company's turnaround that we've been discussing the last several quarters. We remain cautiously optimistic that the pharma and biotech environment is improving which will continue to contribute to our long-term growth.” Morris added, “In addition to our core business, we made

Exhibit 99.1
significant strides in monetizing our data platform, establishing an additional revenue stream that can be transformative for the Company.”

David Miller, CFO of Champions, added, “We continued to deliver strong financial results in our second quarter as revenue increased 17% to $13.5M while we reduced total costs by $771,000. As a result, we recorded adjusted EBITDA of $1.1 million.” Miller added, “With the renewed underlying strength in our core business coupled with the expected revenue contribution from our data platform, we're projecting revenue growth for the year of at least 10% - 15%.”

Second Fiscal Quarter Financial Results

Total revenue for the second quarter of fiscal 2025 was $13.5 million compared to $11.6 million for the same period last year, an increase of 17%. The combination of operational improvements and efficiencies implemented, which led to an increase in our revenue conversion percentage, and the acceleration in our bookings, generated an increase in revenue for both the three months and six months ended October 31, 2024. Total costs and operating expenses for the second quarter of fiscal 2025 were $12.8 million compared to $13.5 million for the second quarter of fiscal 2024, a decrease of $771,000 or 5.7%.

For the second quarter of fiscal 2025, Champions reported income from operations of $732,000, including $9,000 in stock-based compensation and $399,000 in depreciation and amortization expenses, compared to a loss from operations of $2.0 million, inclusive of $53,000 in stock-based compensation and $484,000 in depreciation and amortization expenses, in the second quarter of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported adjusted EBITDA of $1.1 million for the second quarter of fiscal 2025 compared to an adjusted EBITDA loss of $1.4 million in the second quarter of fiscal 2024.

Cost of oncology services was $7.4 million for the three-months ended October 31, 2024, an increase of $810,000, or 12.2% compared to $6.6 million for the three-months ended October 31, 2023. The increase in cost of oncology services was primarily from an increase in mice and lab costs to support revenue growth. For the three-months ended October 31, 2024, total margin was 45% compared to 43% for the three-months ended October 31, 2023. The improved margin resulted primarily from an increase in revenue and a lower cost base due to operational efficiencies implemented, but was under some specific pressure due to the cost of humanized mice.

Research and development expense for the three-months ended October 31, 2024 was $1.7 million, a decrease of $826,000 or 32.8%, compared to $2.5 million for the three-months ended October 31, 2023. The decrease was primarily due to reduced investment in research and development, including our target discovery program. Sales and marketing expense for the three-months ended October 31, 2024 was $1.8 million, a slight decrease of $44,000, or 2.5%, compared to $1.8 million for the three-months ended October 31, 2023. General and administrative expense for the three-months ended October 31, 2024 was $1.9 million, a decrease of $711,000, or 27.3%, compared to $2.6 million for the three-months ended October 31, 2023. The decrease was primarily from a decline in compensation and recruitment expenses and a one-time reduction in our credit loss reserve.

Net cash used in operating activities was approximately $283,000 for the three-months ended October 31, 2024 and was primarily due to an increase in accounts receivable and a decrease in accounts payable offset by net income for the quarter. Net changes in our working capital accounts were in the ordinary course of business. Net cash used in investing activities for the three-months ended October 31, 2024 was approximately $94,000 and was for lab and computer equipment. Net cash provided by

Exhibit 99.1
financing activities for the three-months ended October 31, 2024 was approximately $239,000 resulting primarily from proceeds from options exercise.

The Company ended the quarter with cash on hand of approximately $2.8 million. The Company has no debt.

Year-to-Date Financial Results

Total revenue for the first half of fiscal 2025 was $27.6 million compared to $24.1 million for the same period last year, an increase of 14.2%. Total costs and operating expenses for the first half of fiscal 2025 were $25.5 million compared to $28.6 million for the first half of fiscal 2024, a decrease of $3.2 million or 11.0%.

For the first half of fiscal 2025, Champions reported income from operations of $2.1 million, including $267,000 in stock-based compensation and $848,000 in depreciation and amortization expenses, compared to a loss from operations of $4.5 million, inclusive of $476,000 in stock-based compensation and $929,000 in depreciation and amortization expenses, in the first half of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported adjusted EBITDA of $3.2 million for the first half of fiscal 2025 compared to an adjusted EBITDA loss of $3.1 million in the first half of fiscal 2024.

Cost of oncology services was $14.5 million for the six-months ended October 31, 2024, an increase of
$198,000, or 1.4% compared to $14.3 million for the six-months ended October 31, 2023. The increase in cost of oncology services was primarily from an increase in mice costs. For the six-months ended October 31, 2024, total margin was 47% compared to 41% for the six-months ended October 31, 2023. The improved margin resulted primarily from a combination of an increase in revenue while minimizing cost increases due to operational efficiencies implemented and other cost reduction initiatives.

Research and development expense for the six-months ended October 31, 2024 was $3.1 million, a decrease of $2.2 million or 40.8%, compared to $5.3 million for the six-months ended October 31, 2023. The decrease was primarily due to reduced investment in research and development in non-essential services, including our target discovery program. Sales and marketing expense for the six-months ended October 31, 2024 was $3.4 million, a slight decrease of $61,000, or 1.7%, compared to $3.5 million for the six-months ended October 31, 2023. General and administrative expense for the six-months ended October 31, 2024 was $4.4 million, a decrease of $1.1 million, or 20.3%, compared to $5.5 million for the six-months ended October 31, 2023. The decrease was primarily from a reduction in compensation, recruitment, and stock-based compensation expenses.


Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EST (1:30 p.m. PST) to discuss its second quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610, or provide the verbal reference "Champions Oncology".
Full details of the Company’s financial results will be available by or before December 16, 2024 in the Company’s Form 10-Q at www.championsoncology.com.


Exhibit 99.1
* Non-GAAP Financial Information
See the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP income (loss) per share amounts for the three and six months ended October 31, 2024 and 2023. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company’s basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income (loss) and Non-GAAP income (loss) per share are not, and should not, be viewed as a substitute for similar GAAP items. Champions defines Non-GAAP dilutive income (loss) per share amounts as Non-GAAP net income (loss) divided by the weighted average number of diluted shares outstanding. Champions’ definition of Non-GAAP net income (loss) and Non-GAAP diluted income (loss) per share may differ from similarly named measures used by other companies and may not be applicable for the current reporting period.

About Champions Oncology, Inc.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2024 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.



Champions Oncology, Inc.
(Dollars in thousands)
 
Reconciliation of GAAP to Non-GAAP Net Income (Loss) (Unaudited)
 
 Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
Net income (loss) - GAAP$728 $(2,071)$2,041 $(4,637)
Less:
Stock-based compensation9 53 267 476 
Net income (loss) - Non-GAAP$737 $(2,018)$2,308 $(4,161)
  
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
 
 Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
EPS – GAAP, basic$0.05 $(0.15)$0.15 $(0.34)
Less:
Effect of stock-based compensation on EPS— — 0.02 0.04 
EPS - Non-GAAP, basic$0.05 $(0.15)$0.17 $(0.30)
 Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
EPS – GAAP, diluted$0.05 $(0.15)$0.15 $(0.34)
Less:
Effect of stock-based compensation on EPS— — 0.02 0.04 
EPS - Non-GAAP, diluted$0.05 $(0.15)$0.17 $(0.30)
 


Unaudited Condensed Consolidated Statements of Operations (unaudited)
 Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
Oncology services revenue$13,489 $11,573 $27,550 $24,134 
Cost of oncology services7,428 6,618 14,500 14,302 
Research and development1,689 2,515 3,143 5,308 
Sales and marketing1,751 1,795 3,430 3,491 
General and administrative1,889 2,600 4,416 5,540 
Income (loss) from operations732 (1,955)2,061 (4,507)
Other income (expense) 7 (105)11 (91)
Income (loss) before provision for income taxes739 (2,060)2,072 (4,598)
Provision for income taxes11 11 31 39 
Net income (loss)$728 $(2,071)$2,041 $(4,637)
Net income (loss) per common share outstanding  
basic$0.05 $(0.15)$0.15 $(0.34)
and diluted$0.05 $(0.15)$0.15 $(0.34)
Weighted average common shares outstanding    
basic13,593,766 13,497,061 13,593,766 13,529,629 
and diluted13,969,967 13,497,061 14,006,173 13,529,629 
 


Condensed Consolidated Balance Sheets
 
October 31, 2024April 30, 2024
(unaudited)
Cash and cash equivalents$2,754 $2,618 
Accounts receivable, net10,470 9,526 
Other current assets860 1,495 
Total current assets14,084 13,639 
Operating lease right-of-use assets, net5,669 6,252 
Property and equipment, net4,967 5,721 
Other long term assets185 185 
Goodwill335 335 
Total assets$25,240 $26,132 
Accounts payable and accrued liabilities$7,089 $7,960 
Current portion of operating lease liabilities1,401 1,337 
Other current liabilities 151 150 
Deferred revenue10,220 12,094 
Total current liabilities18,861 21,541 
Non-current operating lease liabilities5,374 6,093 
Other Non-current Liability324 401 
Total liabilities24,559 28,035 
Stockholders’ equity (deficit)681 (1,903)
Total liabilities and stockholders’ equity (deficit)$25,240 $26,132 
 


Unaudited Condensed Consolidated Statements of Cash Flows (unaudited)
 
Six Months Ended
October 31,
 20242023
Cash flows from operating activities:  
Net income (loss)$2,041 $(4,637)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operations:  
Stock-based compensation expense267 476 
Operating lease right-of use assets583 502 
Depreciation and amortization expense848 929 
Loss on disposal of equipment— 65 
Allowance for doubtful accounts and estimated credit losses(280)234 
Changes in operating assets and liabilities(3,431)(971)
Net cash provided by (used in) operating activities28 (3,402)
Cash flows from investing activities:
Purchases of property and equipment(94)(747)
Net cash used in investing activities:(94)(747)
Cash flows from financing activities:  
Repurchases of common stock— (634)
Proceeds from the exercise of stock options276 252 
Finance lease payments(74)(74)
Net cash provided by (used in) financing activities:202 (456)
Net increase (decrease) in cash136 (4,605)
Cash at beginning of period2,618 10,118 
Cash at the end of period$2,754 $5,513 


v3.24.3
Cover Page
Dec. 11, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 11, 2024
Entity Registrant Name CHAMPIONS ONCOLOGY, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-11504
Entity Tax Identification Number 52-1401755
Entity Address, Address Line One 1 University Plaza, Suite 307
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 808-8400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000771856
Amendment Flag false
Document Information [Line Items]  
Document Period End Date Dec. 11, 2024
Champions Oncology (NASDAQ:CSBR)
過去 株価チャート
から 11 2024 まで 12 2024 Champions Oncologyのチャートをもっと見るにはこちらをクリック
Champions Oncology (NASDAQ:CSBR)
過去 株価チャート
から 12 2023 まで 12 2024 Champions Oncologyのチャートをもっと見るにはこちらをクリック